 |
|
|
|
|
|
|
|
|
|
|
|
|
Update on Protocol 0107- 488 |
|
|
| |
A Phase I, Open-Label Clinical Trial of the Safety and Tolerability of Single Escalating Doses of Autologous CD4 T Cells Transduced with VRX496 in HIV-Positive Subjects (In-depth review and public discussion at the September 2001 RAC meeting) |
|
|
| |
Boro Dropulic, Ph.D., VIRxSYS Corporation, Gaithersburg, MD |
|
|
| |
Webcast
Slides
|
|
| |
|
|
|
|
Discussion of Human Gene Transfer Protocol #0404-642 |
|
|
| |
A Phase I Trial of Gene Transfer during VAD Support with SERCA2a |
|
|
| |
Barry London, M.D., Ph.D., University of Pittsburgh Medical Center |
|
|
| |
Webcast
Slides
|
|
| |
|
|
|
Introduction to Upcoming Safety Symposium |
|
|
| |
Safety Considerations in Recombinant DNA Research with Highly Pathogenic Viruses |
|
|
| |
Kanta Subbarao, M.D., M.P.H., Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH
Christina Cassetti, Ph.D., Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH |
|
|
| |
Webcast
Slides set 1
Slides set 2
Slides set 3
|
|
| |
|
|
|
|
Discussion of Human Gene Transfer Protocol #0403-633 |
|
|
| |
A Phase I Trial of Immunotherapy with BHT-3009 Alone or Combined with Atorvastatin in Patients with Multiple Sclerosis |
|
|
| |
Timothy L. Vollmer, MD, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center |
|
|
| |
Webcast
Slides set 1
Slides set 2
|
|
| |
|
|
|
|
Discussion of Human Gene Transfer Protocol #0404-641 |
|
|
| |
A Phase I, Open-Label, Nonrandomized, Dose-Escalation, Multicenter Therapeutic Trial of the Safety, Immunogenicity and Efficacy of GI-4000, an Inactivated Recombinant Saccharomyces cerevisiae Immunotherapeutic Expressing Three Different Mutations of the Ras Oncoprotein, in Patients with Solid Tumors Expressing Mutations in Ras |
|
|
| |
Bert O'Neil, M.D., University of North Carolina School of Medicine, Chapel Hill, NC |
|
|
| |
Webcast
Slides
|
|
| |
|
|
|
Update on the RAC Gene Transfer Clinical Trial Design Working Group |
|
|
| |
David DeMets, Ph.D., NIH RAC |
|
|
| |
Webcast
|
|
| |
|
|
|
ADJOURN |
|
| |
|
Top of Page |
| |
